Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

Nicoll, James A.R., Wilkinson, David, Holmes, Clive, Steart, Phil, Markham, Hannah, Weller, Roy O.·2003·Nature Medicine
DOI 10.1038/nm840

Cited by (1,000)

Items 101–200 of 1,000

  1. Virus-like particle vaccinology, from bench to bedside
    Mona Omar Mohsen, Martin F. Bachmann · 2022 · Cellular and Molecular Immunology
  2. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy
    Weller, Roy O., Boche, Delphine, Nicoll, James A. R. · 2009 · Acta Neuropathologica
  3. Dysregulation of Histone Acetylation in the APP/PS1 Mouse Model of Alzheimer's Disease
    Yitshak I. Francis, Mauro Fà, Haider Ashraf, Hong Zhang, Agnieszka Staniszewski, David S. Latchman, Ottavio Arancio · 2009 · Journal of Alzheimer s Disease
  4. Microglia actions in Alzheimer's disease
    Prokop, Stefan, Miller, Kelly R., Heppner, Frank L. · 2013 · Acta Neuropathologica
  5. Can the immune system be harnessed to repair the CNS?
    Phillip G. Popovich, Erin E. Longbrake · 2008 · Nature reviews. Neuroscience
  6. Immunotherapeutic Approaches for Alzheimer’s Disease
    Wisniewski, Thomas, Goñi, Fernando · 2015 · Neuron
  7. Reduction of Soluble Aβ and Tau, but Not Soluble Aβ Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles
    Salvatore Oddo, Vitaly Vasilevko, Antonella Caccamo, Masashi Kitazawa, David H. Cribbs, Frank M. LaFerla · 2006 · Journal of Biological Chemistry
  8. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease
    Martin Rhys Farlow, Steven Edward Arnold, Christopher H. van Dyck, Paul S. S. Aisen, B. Joy Snider, Anton P. Porsteinsson, Stuart W. Friedrich, Robert A. Dean, Celedon Gonzales, Gopalan Sethuraman et al. · 2012 · Alzheimer s & Dementia
  9. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
    Eric H. Karran, John Hardy · 2014 · Annals of Neurology
  10. Cortical and Leptomeningeal Cerebrovascular Amyloid and White Matter Pathology in Alzheimer’s Disease
    Alex E. Roher, Yu‐Min Kuo, Chera L. Esh, Carmen Knebel, Nicole Weiss, Walter M. Kalback, Dean C. Luehrs, Jennifer Childress, Thomas G. Beach, Roy O. Weller et al. · 2003 · Molecular Medicine
  11. Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model
    Boutajangout, Allal, Quartermain, David, Sigurdsson, Einar M. · 2010 · The Journal of Neuroscience
  12. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy
    Jürgen Götz, Johannes Rolf Streffer, Della C. David, A Schild, Frédéric J. Hoerndli, Luis Pennanen, Pascal Kurosinski, F Chen · 2004 · Molecular Psychiatry
  13. Inflammatory components in human Alzheimer’s disease and after active amyloid-β42 immunization
    Zotova, Elina, Bharambe, Viraj, Cheaveau, Matthew, Morgan, William, Holmes, Clive, Harris, Scott, Neal, James W., Love, Seth, Nicoll, James A. R., Boche, Delphine · 2013 · Brain
  14. Activation of Microglia Acidifies Lysosomes and Leads to Degradation of Alzheimer Amyloid Fibrils
    Majumdar, Amitabha, Cruz, Dana, Asamoah, Nikiya, Buxbaum, Adina, Sohar, Istvan, Lobel, Peter, Maxfield, Frederick R. · 2007 · Molecular Biology of the Cell
  15. Biomarkers of Alzheimer disease in plasma
    Michael C. Irizarry · 2004 · NeuroRx
  16. Aβ Species Removal After Aβ <sub>42</sub> Immunization
    Nicoll, James A. R., Barton, Edward, Boche, Delphine, Neal, Jim W., Ferrer, Isidro, Thompson, Petrina, Vlachouli, Christina, Wilkinson, David, Bayer, Antony, Games, Dora et al. · 2006 · Journal of Neuropathology &amp; Experimental Neurology
  17. The significance of neuroinflammation in understanding Alzheimer’s disease
    Piet Eikelenboom, Robert Veerhuis, Wiep Scheper, Annemieke J.M. Rozemüller, Willem A. van Gool, Jeroen J.M. Hoozemans · 2006 · Journal of Neural Transmission
  18. Alzheimer disease: progress or profit?
    Claire Mount, Christian Downton · 2006 · Nature Medicine
  19. Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy
    Theunis, Clara, Crespo-Biel, Natalia, Gafner, Valérie, Pihlgren, Maria, López-Deber, María Pilar, Reis, Pedro, Hickman, David T., Adolfsson, Oskar, Chuard, Nathalie, Ndao, Dorin Mlaki et al. · 2013 · PLoS ONE
  20. Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy
    Elina Zotova, James A. R. Nicoll, Raj N. Kalaria, Clive Holmes, Delphine Boche · 2010 · Alzheimer s Research & Therapy
  21. Microglia and neuroprotection: implications for Alzheimer's disease
    Wolfgang J. Streit · 2005 · Brain Research Reviews
  22. Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
    Bruno J. Vellas, Ronald S. Black, Leon J. Thal, Nick C. Fox, Maki Daniels, G. McLennan, C. Tompkins, Christopher W. Leibman, M. Pomfret, Michael Grundman · 2009 · Current Alzheimer Research
  23. Alzheimer Disease
    Liana G. Apostolova · 2016 · CONTINUUM Lifelong Learning in Neurology
  24. Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ Precursor Protein (APP) Transgenic Mice
    Edward B. Lee, Lewis Z. Leng, Bin Zhang, Linda K. Kwong, John Q. Trojanowski, Ted G. Abel, Virginia M.‐Y. Lee · 2005 · Journal of Biological Chemistry
  25. Active and passive immunotherapy for neurodegenerative disorders
    Brody, David L., Holtzman, David M. · 2008 · Annual Review of Neuroscience
  26. Neuroinflammation in Alzheimer's Disease: Mechanisms, Pathologic Consequences, and Potential for Therapeutic Manipulation
    Kenneth Hensley · 2010 · Journal of Alzheimer s Disease
  27. Neuronal damage in brain inflammation
    Aktas, Orhan, Ullrich, Oliver, Infante-Duarte, Carmen, Nitsch, Robert, Zipp, Frauke · 2007 · Archives of Neurology
  28. Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests
    Bates, K A, Verdile, G, Li, Q-X, Ames, D, Hudson, P, Masters, C L, Martins, R N · 2009 · Molecular Psychiatry
  29. Protease-Activated Drug Development
    Ki Young Choi, Magdalena Swierczewska, Seulki Lee, Xiaoyuan Shawn Chen · 2012 · Theranostics
  30. Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms
    Attems, Johannes · 2005 · Acta Neuropathologica
  31. Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design
    Emily M. Plummer, Marianne Manchester · 2010 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
  32. Persistent Amyloidosis following Suppression of Aβ Production in a Transgenic Model of Alzheimer Disease
    Jankowsky, Joanna L, Slunt, Hilda H, Gonzales, Victoria, Savonenko, Alena V, Wen, Jason C, Jenkins, Nancy A, Copeland, Neal G, Younkin, Linda H, Lester, Henry A, Younkin, Steven G et al. · 2005 · PLoS Medicine
  33. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis
    Makoto Urushitani, Samer Abou Ezzi, Jean‐Pierre Julien · 2007 · Proceedings of the National Academy of Sciences
  34. Pathogenesis of Alzheimer's disease.
    Russell Howard Swerdlow · 2007 · PubMed Central
  35. Cerebral amyloid angiopathy related inflammation: three case reports and a review
    KongKhi Chung, N. E. Anderson, David O. Hutchinson, Beth J. L. Synek, P. Alan Barber · 2010 · Journal of Neurology Neurosurgery & Psychiatry
  36. Inflammatory Aspects of Alzheimer Disease and Other Neurodegenerative Disorders
    Claudia Schwab, Patrick L. McGeer · 2008 · Journal of Alzheimer s Disease
  37. Molecular neurology of prion disease
    John Collinge · 2005 · Journal of Neurology Neurosurgery & Psychiatry
  38. IgG-Assisted Age-Dependent Clearance of Alzheimer's Amyloid β Peptide by the Blood–Brain Barrier Neonatal Fc Receptor
    Rashid Deane, Abhay P. Sagare, Katie Hamm, Margaret Parisi, Barbra LaRue, Huang Guo, Zhenhua Wu, David M. Holtzman, Berislav V. Zloković · 2005 · Journal of Neuroscience
  39. Emerging Concepts in Alzheimer's Disease
    Harry V. Vinters · 2014 · Annual Review of Pathology Mechanisms of Disease
  40. Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors
    Haythum Osama Tayeb, Hyun Duk Yang, Bruce Heimburger Price, Frank I. Tarazi · 2011 · Pharmacology & Therapeutics
  41. Alzheimer's Disease Aβ Vaccine Reduces Central Nervous System Aβ Levels in a Non-Human Primate, the Caribbean Vervet
    Lemere, Cynthia A., Beierschmitt, Amy, Iglesias, Melitza, Spooner, Edward T., Bloom, Jeanne K., Leverone, Jodi F., Zheng, Jessica B., Seabrook, Timothy J., Louard, Dora, Li, Diana et al. · 2004 · The American Journal of Pathology
  42. Immunotherapy for Alzheimer’s disease: Key Symposium: Immunotherapy for Alzheimer’s disease
    Morgan, D. · 2011 · Journal of Internal Medicine
  43. The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease
    Drachman, David A. · 2014 · Alzheimer's &amp; Dementia
  44. Powerful beneficial effects of macrophage colony-stimulating factor on -amyloid deposition and cognitive impairment in Alzheimer's disease
    Boissonneault, V., Filali, M., Lessard, M., Relton, J., Wong, G., Rivest, S. · 2008 · Brain
  45. 1α,25-dihydroxyvitamin D3 Interacts with Curcuminoids to Stimulate Amyloid-β Clearance by Macrophages of Alzheimer's Disease Patients
    Ava Masoumi, Benjamin Goldenson, Senait Ghirmai, Hripsime Avagyan, Justin Zaghi, Ken Abel, Xueying Zheng, Araceli Espinosa de los Monteros, Michelle Mahanian, Philip T. Liu et al. · 2009 · Journal of Alzheimer s Disease
  46. Immunotherapeutic Approaches to Alzheimer's Disease
    Alon Monsonego, Howard L. Weiner · 2003 · Science
  47. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease
    Farfara, D., Lifshitz, V., Frenkel, D. · 2008 · Journal of Cellular and Molecular Medicine
  48. Metabolism of amyloid-β peptide and Alzheimer's disease
    Nobuhisa Iwata, Makoto Higuchi, Takaomi C. Saido · 2005 · Pharmacology & Therapeutics
  49. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain
    D’Andrea, Michael R, Cole, Gregory M, Ard, March D · 2004 · Neurobiology of Aging
  50. Mouse Models of Alzheimer’s Disease
    Yokoyama, Miyabishara, Kobayashi, Honoka, Tatsumi, Lisa, Tomita, Taisuke · 2022 · Frontiers in Molecular Neuroscience
  51. Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/-Knock-Out Mice
    Pritam Das, VICTOR G. HOWARD, Nicole Loosbrock, Dennis W. Dickson, Michael Paul Murphy, Todd Eliot Golde · 2003 · Journal of Neuroscience
  52. Transgenic models of Alzheimer’s disease: Learning from animals
    Tara L. Spires‐Jones, Bradley T. Hyman · 2005 · NeuroRx
  53. Anti-A 42- and anti-A 40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model
    Yona Levites · 2005 · Journal of Clinical Investigation
  54. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease
    James A. R. Nicoll, George R. Buckland, Charlotte H. Harrison, Anton M. Page, Scott Harris, Seth Love, James Neal, Clive Holmes, Delphine Boche · 2019 · Brain
  55. Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration
    Wilcock, Donna M, Munireddy, Sanjay K, Rosenthal, Arnon, Ugen, Kenneth E, Gordon, Marcia N, Morgan, Dave · 2004 · Neurobiology of Disease
  56. Alzheimer's disease drug development and the problem of the blood‐brain barrier
    William M. Pardridge · 2009 · Alzheimer s & Dementia
  57. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives
    Yan‐Jiang Wang, Huadong Zhou, Xin‐Fu Zhou · 2006 · Drug Discovery Today
  58. The Cerebral β-Amyloid Angiopathies: Hereditary and Sporadic
    Sandy Zhang-Nunes, Marion L. C. Maat–Schieman, Sjoerd G. van Duinen, Raymund A.C. Roos, Matthew P. Frosch, Steven Mark Greenberg · 2006 · Brain Pathology
  59. The Threshold Theory for Parkinson's Disease
    Simone Engelender, Ole Isacson A · 2016 · Trends in Neurosciences
  60. Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics
    Matthew L. Hemming, Joshua Eric Elias, Steven P. Gygi, Dennis J. Selkoe · 2009 · PLoS ONE
  61. Amyloid-β Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients
    Rebekah Patton, Walter M. Kalback, Chera L. Esh, Tyler A. Kokjohn, Gregory D. Van Vickle, Dean C. Luehrs, Yu‐Min Kuo, John C. Lopez, Daniel C. Brune, Isidró Ferrer et al. · 2006 · American Journal Of Pathology
  62. Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease
    Eric Siemers, Stuart W. Friedrich, Robert A. Dean, Celedon Gonzales, Martin Rhys Farlow, Steven M. Paul, Ronald Bradley Demattos · 2010 · Clinical Neuropharmacology
  63. Alzheimer’s Disease, Oligomers, and Inflammation
    Gianluigi Forloni, Claudia Balducci · 2018 · Journal of Alzheimer s Disease
  64. The Second-Generation Active A Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects
    Christoph Wießner, Karl‐Heinz Wiederhold, Alain C. Tissot, P. Frey, S. Danner, Laura H. Jacobson, Gary T. Jennings, Rainer M. Lüönd, Rainer Ortmann, Julia Reichwald et al. · 2011 · Journal of Neuroscience
  65. The Canine (Dog) Model of Human Aging and Disease: Dietary, Environmental and Immunotherapy Approaches
    Carl W. Cotman, Elizabeth Head · 2008 · Journal of Alzheimer s Disease
  66. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS
    François Gros‐Louis, Geneviève Soucy, Roxanne Larivière, Jean‐Pierre Julien · 2010 · Journal of Neurochemistry
  67. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration
    Jindong Ding, Lincoln V. Johnson, Rolf Herrmann, Sina Farsiu, Stephanie G. Smith, Marybeth Groelle, Brian E. Mace, Patrick M. Sullivan, Jeffrey Adam Jamison, Una Kelly et al. · 2011 · Proceedings of the National Academy of Sciences
  68. Cerebral microbleeds: overview and implications in cognitive impairment
    Sergi Martínez‐Ramírez, Steven Mark Greenberg, Anand Viswanathan · 2014 · Alzheimer s Research & Therapy
  69. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer disease
    Dan Frenkel, Ruth Maron, David S. Burt, Howard L. Weiner · 2005 · Journal of Clinical Investigation
  70. Targeting microglia for the treatment of Alzheimer’s Disease
    Wes, Paul D., Sayed, Faten A., Bard, Frédérique, Gan, Li · 2016 · Glia
  71. Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
    Dionisio-Santos, Dawling A., Olschowka, John A., O’Banion, M. Kerry · 2019 · Journal of Neuroinflammation
  72. T-Cells in Alzheimer's Disease
    Town, Terrence, Tan, Jun, Flavell, Richard A., Mullan, Mike · 2005 · NeuroMolecular Medicine
  73. Curcuminoids enhance amyloid-β uptake by macrophages of Alzheimer's disease patients
    Laura Zhang, Milan Fiala, John Richard Cashman, James William Sayre, Araceli Espinosa de los Monteros, Michelle Mahanian, Justin Zaghi, Vladimir Badmaev, Michael C. Graves, George W. Bernard et al. · 2006 · Journal of Alzheimer s Disease
  74. White Matter Changes in Dementia: Role of Impaired Drainage of Interstitial Fluid
    Roy O. Weller, Cheryl A. Hawkes, Raj N. Kalaria, David John Werring, Roxana Octavia Carare · 2014 · Brain Pathology
  75. Invasion of Hematopoietic Cells into the Brain of Amyloid Precursor Protein Transgenic Mice
    Anna Katharina Stalder, Florian Ermini, Luca Bondolfi, Werner Krenger, Guido J. Burbach, Thomas Deller, Janaky Coomaraswamy, Matthias Staufenbiel, Regine M. Landmann, Mathias Jucker · 2005 · Journal of Neuroscience
  76. Prototype Alzheimer’s Disease Vaccine Using the Immunodominant B Cell Epitope from β-Amyloid and Promiscuous T Cell Epitope Pan HLA DR-Binding Peptide
    Michael G. Agadjanyan, Anahit Ghochikyan, Irina Petrushina, Vitaly Vasilevko, Nina Movsesyan, Mikayel Mkrtichyan, Tommy Saing, David H. Cribbs · 2005 · The Journal of Immunology
  77. Toxic Human Islet Amyloid Polypeptide (h-IAPP) Oligomers Are Intracellular, and Vaccination to Induce Anti-Toxic Oligomer Antibodies Does Not Prevent h-IAPP–Induced β-Cell Apoptosis in h-IAPP Transgenic Mice
    Chia‐Yu Lin, Tatyana Gurlo, Rakez Kayed, Alexandra E. Butler, Leena Haataja, Charles G. Glabe, Peter C. Butler · 2007 · Diabetes
  78. The endocannabinoid system as a target for the treatment of neurodegenerative disease
    Emma L. Scotter, Mary E. Abood, Michelle Glass · 2010 · British Journal of Pharmacology
  79. Neuroinflammatory perspectives on the two faces of Alzheimer?s disease
    Piet Eikelenboom, Willem A. van Gool · 2004 · Journal of Neural Transmission
  80. Is inhibition of the renin–angiotensin system a new treatment option for Alzheimer's disease?
    Patrick G. Kehoe, Gordon Keith Wilcock · 2007 · The Lancet Neurology
  81. Extracellular Chaperones and Proteostasis
    Amy R. Wyatt, Justin J. Yerbury, Heath W. Ecroyd, Mark R. Wilson · 2013 · Annual Review of Biochemistry
  82. Brain insulin resistance: role in neurodegenerative disease and potential for targeting
    Hölscher, Christian · 2020 · Expert Opinion on Investigational Drugs
  83. Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology?a pilot study
    Johannes Attems, K. A. Jellinger · 2004 · Acta Neuropathologica
  84. A brief overview of amyloids and Alzheimer's disease
    Sian‐Yang Ow, Dave E. Dunstan · 2014 · Protein Science
  85. Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies
    Adalbert, Robert, Nogradi, Antal, Babetto, Elisabetta, Janeckova, Lucie, Walker, Simon A., Kerschensteiner, Martin, Misgeld, Thomas, Coleman, Michael P. · 2009 · Brain
  86. Microglia as a Potential Bridge between the Amyloid β‐Peptide and Tau
    Masashi Kitazawa, Tritia R. Yamasaki, Frank M. LaFerla · 2004 · Annals of the New York Academy of Sciences
  87. Galantamine-induced Amyloid-β Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine Receptors
    Takata, Kazuyuki, Kitamura, Yoshihisa, Saeki, Mana, Terada, Maki, Kagitani, Sachiko, Kitamura, Risa, Fujikawa, Yasuhiro, Maelicke, Alfred, Tomimoto, Hidekazu, Taniguchi, Takashi et al. · 2010 · Journal of Biological Chemistry
  88. Amyloid β-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin
    Malito, E., Hulse, R. E., Tang, W.-J. · 2008 · Cellular and Molecular Life Sciences
  89. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice
    Andreas Muhs, David T. Hickman, Maria Pihlgren, Nathalie Chuard, Valérie Giriens, Carine Meerschman, Ingrid Van der Auwera, Fred VAN LEUVEN, Masae Sugawara, Marie-Catherine Weingertner et al. · 2007 · Proceedings of the National Academy of Sciences
  90. Current approaches in the treatment of Alzheimer's disease
    Reena S. Shah, Hyoung‐gon Lee, Xiongwei Zhu, George L. Perry, Mark A. Smith, Rudy J. Castellani · 2008 · Biomedicine & Pharmacotherapy
  91. Young microglia restore amyloid plaque clearance of aged microglia
    Daria, Anna, Colombo, Alessio, Llovera, Gemma, Hampel, Heike, Willem, Michael, Liesz, Arthur, Haass, Christian, Tahirovic, Sabina · 2017 · The EMBO Journal
  92. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice
    Boimel, Moran, Grigoriadis, Nikolaos, Lourbopoulos, Athanasios, Haber, Esther, Abramsky, Oded, Rosenmann, Hanna · 2010 · Experimental Neurology
  93. Cerebral amyloid angiopathy and its co-occurrence with Alzheimer's disease and other cerebrovascular neuropathologic changes
    Willa D. Brenowitz, Peter T. Nelson, Lilah M. Besser, Katherine Heller, Walter A. Kukull · 2015 · Neurobiology of Aging
  94. PET amyloid-beta imaging in preclinical Alzheimer's disease
    Andrei G. Vlassenko, Tammie L.S. Benzinger, John C. Morris · 2011 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  95. The expanding role of BDNF: a therapeutic target for Alzheimer's disease?
    Fabio Fumagalli, Giorgio Racagni, Marco Andrea Riva · 2005 · The Pharmacogenomics Journal
  96. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
    John Howard Sampson, Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, Darell D. Bigner · 2008 · Seminars in Immunology
  97. A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease
    Black, Ronald S., Sperling, Reisa A., Safirstein, Beth, Motter, Ruth N., Pallay, Allan, Nichols, Alice, Grundman, Michael · 2010 · Alzheimer Disease &amp; Associated Disorders
  98. Memory loss in Alzheimer’s disease: implications for development of therapeutics
    Carl A. Gold, Andrew E. Budson · 2008 · Expert Review of Neurotherapeutics
  99. Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage
    Mark O. McCarron, James A. R. Nicoll · 2004 · The Lancet Neurology
  100. Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive Aβ Immunotherapy on Their Clearance
    Thierry Bussière, Frédérique Bard, Robin Barbour, Henry Grajeda, Terry Guido, Karen Khan, Dale Schenk, Dora Games, Peter A. Seubert, Manuel Buttini · 2004 · American Journal Of Pathology